Dong Yaru, Ishikawa Hitoshi, Wu Yazhen, Yoshitomi Takeshi
Department of Ophthalmology, Akita University School of Medicine, 1-1-1 Hondo, Akita, Akita 010-8543, Japan.
Exp Eye Res. 2007 Jun;84(6):1039-46. doi: 10.1016/j.exer.2007.01.010. Epub 2007 Jan 27.
Topical application of levobunolol hydrochloride, a beta-adrenergic antagonist used for treatment of glaucoma, is reported to increase ocular blood flow. We studied the mechanism of levobunolol-induced vasodilation in arterial smooth muscle. The effects of levobunolol or other agents on isolated, pre-contracted rabbit ciliary artery were investigated using an isometric tension recording method. The effects of the same agents on intracellular free calcium (Ca(2+)) in cultured human aortic smooth muscle cells were also studied by fluorophotometry. Levobunolol relaxed ciliary artery rings that were pre-contracted with either high-K solution, 1microM histamine, 10microM phenylephrine, or 100nM endothelin-1. The relaxation induced by levobunolol was concentration-dependent over the range of 10microM to 0.3mM. Inhibition of endothelial nitric oxide synthase or denudation of the endothelium did not affect this relaxation. Histamine-induced contractions were inhibited by the histamine H(1) antagonist pyrilamine. Radioligand binding experiments showed that levobunolol did not bind to the H(1) receptor. Further, histamine induced transient contraction in Ca(2+)-free solution, and levobunolol inhibited this contraction by 74.6+/-11.0%. In cultured smooth muscle cells in the presence of extracellular Ca(2+), levobunolol significantly inhibited the histamine-induced elevation of Ca(2+). However, it did not inhibit the increase of Ca(2+) in histamine-stimulated cells incubated in Ca(2+)-free solution. These results indicate that levobunolol may relax rabbit ciliary artery by two different mechanisms. First, the relaxation could be due to the blockade of Ca(2+) entry through non-voltage-dependent Ca(2+) channels. Second, levobunolol may change the Ca(2+) sensitivity of vascular smooth muscle cells.
据报道,用于治疗青光眼的β-肾上腺素能拮抗剂盐酸左布诺洛尔的局部应用可增加眼部血流量。我们研究了左布诺洛尔诱导动脉平滑肌血管舒张的机制。使用等长张力记录法研究了左布诺洛尔或其他药物对离体预收缩兔睫状动脉的影响。还通过荧光光度法研究了相同药物对培养的人主动脉平滑肌细胞内游离钙([Ca(2+)]i)的影响。左布诺洛尔使预先用高钾溶液、1μM组胺、10μM去氧肾上腺素或100nM内皮素-1预收缩的睫状动脉环舒张。左布诺洛尔诱导的舒张在10μM至0.3mM范围内呈浓度依赖性。抑制内皮型一氧化氮合酶或去除内皮均不影响这种舒张。组胺诱导的收缩被组胺H(1)拮抗剂吡拉明抑制。放射性配体结合实验表明左布诺洛尔不与H(1)受体结合。此外,组胺在无钙溶液中诱导短暂收缩,左布诺洛尔抑制这种收缩达74.6±11.0%。在存在细胞外钙的培养平滑肌细胞中,左布诺洛尔显著抑制组胺诱导的[Ca(2+)]i升高。然而,它不抑制在无钙溶液中孵育的组胺刺激细胞中[Ca(2+)]i的增加。这些结果表明左布诺洛尔可能通过两种不同机制使兔睫状动脉舒张。首先,舒张可能是由于通过非电压依赖性钙通道阻断钙内流。其次,左布诺洛尔可能改变血管平滑肌细胞的钙敏感性。